ERBB2 and breast carcinoma: The current standard first-line therapy for patients with metastatic HER2-positive breast cancer consists of the chemotherapy agent docetaxel in combination with two HER2-directed therapies, trastuzumab and pertuzumab, and is continued until disease progression or unacceptable toxicity.